Company intelligence / Profile preview
Haima Therapeutics
Cleveland, Ohio, United Stateshaimatherapeutics.com ↗
- Ownership
- Private
- Employees
- ~13
- Development stage
- Other
01
Overview
Developing SynthoPlate, a novel synthetic hemostatic agent that mitigates bleeding by acting at the site of injury and amplifying the body's natural clotting mechanisms
- Therapeutic areas
- Hematology
- Modalities
- Nanoparticle-based synthetic hemostatic technologyPlatelet-inspired therapies
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
DARPA FSHARP programKaloCyte Inc.Case Western Reserve UniversityUniversity of Maryland Baltimore (UMB)Teleflex Incorporated
Beyond the preview
Go deeper on Haima Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Haima Therapeutics.